Shire Plc (SHP)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Shire Plc (SHP) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011964
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:88
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Shire Plc (Shire) is a biotechnology company that focuses on the research, development, manufacturing, marketing, distribution and sale of novel pharmaceuticals to serve patients with rare diseases and other highly specialized conditions. It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases. The company primarily sells its products through pharmaceutical wholesale distributors and large pharmacies, in both the US and Europe. The company operates along with its subsidiaries and representative offices in Europe, the Americas, Asia Pacific, South Africa and other countries. Shire is headquartered in Dublin, Ireland.

Shire Plc (SHP) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Shire Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Shire Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Shire Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Shire Plc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Shire Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Shire Plc, Medical Equipment, Deal Details 12
Venture Financing 12
Lotus Tissue Repair Secures US$26 Million In Series A Financing 12
DBV Technologies Secures US$25.5 Million In Series C Venture Financing Round 13
Partnerships 15
EM Imaging Enters into Licensing Agreement with GE Healthcare and Dyax 15
Zacharon Enters Into Licensing Agreement With Shire For Sensi Pro Assay 16
Shire Enters into Partnership with MicroHealth 17
Equity Offering 18
Dyax Completes Public Offering Of Shares For US$85 Million 18
Dyax Completes Public Offering Of Shares For US$69 Million 19
Dyax Completes Private Placement Of Shares For US$20.5 Million 21
Dyax Completes Private Placement Of Preferred Stock For US$9.5 Million 23
Debt Offering 25
Shire Raises USD3.3 Billion in Public Offering of 1.9% Notes Due 2019 25
Shire Raises USD2.5 Billion in Public Offering of 2.875% Notes Due 2023 27
Shire Raises USD3.3 Billion in Public Offering of 2.4% Notes Due 2021 29
Shire Raises USD3 Billion in Public Offering of 3.2% Notes Due 2026 31
Acquisition 33
Shire May Acquire Radius Health 33
Shire Acquires NPS Pharma for USD5.2 Billion 34
Shire Acquires Lotus Tissue Repair, Developer of Protein Replacement Therapy 36
Shire Completes Acquisition Of Advanced BioHealing 37
Shire Plc – Key Competitors 39
Shire Plc – Key Employees 40
Shire Plc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Joint Venture 48
Recent Developments 49
Strategy And Business Planning 49
Apr 27, 2017: Shire opens new HQ office in Dublin City Centre 49
Dec 06, 2016: Planning permission granted for new Shire manufacturing site in Ireland 50
Nov 22, 2016: Shire to Establish Rare Disease Innovation Hub in Cambridge, Mass. 51
Financial Announcements 52
Oct 27, 2017: Shire Reports Strong Earnings Growth in Q3 2017; Reiterates Full Year Guidance 52
Aug 03, 2017: Shire reports strong Q2 2017 operating results and cash flow; updates full year guidance 56
May 02, 2017: Shire delivers strong Q1 2017 revenue growth while advancing late-stage pipeline 60
Feb 16, 2017: Shire Announces Full Year 2016 Results 65
Nov 01, 2016: Shire Reports Q3 2016 Results with Record Revenues and Reiterates Full Year Non GAAP Guidance 68
Aug 02, 2016: Shire Delivers Strong Q2 2016 Revenue Growth; Upgrades Outlook 71
Corporate Communications 75
Dec 08, 2017: Chief Financial Officer update 75
Dec 08, 2017: Shire: Chief Financial Officer update 76
Dec 01, 2017: Shire Appoints Andreas Busch, Ph D as Head of Research and Development and Chief Scientific Officer 77
Nov 20, 2017: Shire to Appoint Thomas Dittrich as Chief Financial Officer and Member of the Board of Directors 78
Aug 21, 2017: Shire Director and Senior Management Changes 79
Jan 13, 2017: Shire Joins Illinois Biotechnology Innovation Organization as Leadership Sponsor and Adds Shannon Resetich to the Board 80
Jan 03, 2017: Shire Appoints Ian Clark as Non-Executive Director 81
Jun 07, 2016: Shire Announces Directorate change 82
Legal and Regulatory 83
Feb 07, 2017: Shire Responds to US Federal Trade Commission Civil Action 83
Jun 14, 2016: Shire Announces Additional Listing 84
Other Significant Developments 85
Oct 24, 2017: Shire Launches OnePath Patient Portal and Mobile Application 85
Aug 25, 2017: Shire Announces Collaboration with MicroHealth to Address Unique Needs of Hemophilia A and B Patients with Inhibitors 86
Jun 03, 2016: Shire Completes Combination with Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions 87
Appendix 88
Methodology 88
About GlobalData 88
Contact Us 88
Disclaimer 88

List of Tables
Shire Plc, Medical Equipment, Key Facts, 2016 2
Shire Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Shire Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Shire Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Shire Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Shire Plc, Deals By Market, 2011 to YTD 2017 9
Shire Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Lotus Tissue Repair Secures US$26 Million In Series A Financing 12
DBV Technologies Secures US$25.5 Million In Series C Venture Financing Round 13
EM Imaging Enters into Licensing Agreement with GE Healthcare and Dyax 15
Zacharon Enters Into Licensing Agreement With Shire For Sensi Pro Assay 16
Shire Enters into Partnership with MicroHealth 17
Dyax Completes Public Offering Of Shares For US$85 Million 18
Dyax Completes Public Offering Of Shares For US$69 Million 19
Dyax Completes Private Placement Of Shares For US$20.5 Million 21
Dyax Completes Private Placement Of Preferred Stock For US$9.5 Million 23
Shire Raises USD3.3 Billion in Public Offering of 1.9% Notes Due 2019 25
Shire Raises USD2.5 Billion in Public Offering of 2.875% Notes Due 2023 27
Shire Raises USD3.3 Billion in Public Offering of 2.4% Notes Due 2021 29
Shire Raises USD3 Billion in Public Offering of 3.2% Notes Due 2026 31
Shire May Acquire Radius Health 33
Shire Acquires NPS Pharma for USD5.2 Billion 34
Shire Acquires Lotus Tissue Repair, Developer of Protein Replacement Therapy 36
Shire Completes Acquisition Of Advanced BioHealing 37
Shire Plc, Key Competitors 39
Shire Plc, Key Employees 40
Shire Plc, Other Locations 41
Shire Plc, Subsidiaries 41
Shire Plc, Joint Venture 48

★海外企業調査レポート[Shire Plc (SHP)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Himachal Futuristic Communications Ltd (HFCL):企業の財務・戦略的SWOT分析
    Summary Himachal Futuristic Communications Ltd (HFCL) is a manufacturer of telecommunication equipment, optical fiber cables, and intelligent power systems. The company’s optical fiber cables comprise aerial, armoured, FTTx, micro and unarmoured cables. It also provides microwave radios, GPON and so …
  • Vascular Biogenics Ltd (VBLT):企業の財務・戦略的SWOT分析
    Summary Vascular Biogenics Ltd (VBL) is a clinical biopharmaceutical company that discovers, develops and commercializes treatments for cancer. The company’s product pipeline includes VB-111. VBL’s product VB-111 is an anti-angiogenic agent for the specific inhibition of tumor vascular growth for ca …
  • NW Natural Gas Co:企業の戦略的SWOT分析
    NW Natural Gas Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Magellan Health Inc (MGLN):製薬・医療:M&Aディール及び事業提携情報
    Summary Magellan Health Inc (Magellan) is a health care management company which manages behavioral health, radiology and specialty pharmaceuticals, and public sector pharmacy benefits programs. The company provides behavioral healthcare, specialty solutions, and pharmacy management services and int …
  • NCR Corporation:戦略・SWOT・企業財務分析
    NCR Corporation - Strategy, SWOT and Corporate Finance Report Summary NCR Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Qualcomm Ventures:企業のM&A・事業提携・投資動向
    Qualcomm Ventures - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Qualcomm Ventures Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Transport for London:企業の戦略的SWOT分析
    Transport for London - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Hibbett Sports Inc:戦略・SWOT・企業財務分析
    Hibbett Sports Inc - Strategy, SWOT and Corporate Finance Report Summary Hibbett Sports Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • transcosmos Inc:企業の戦略・SWOT・財務分析
    transcosmos Inc - Strategy, SWOT and Corporate Finance Report Summary transcosmos Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Informa PLC (INF):企業の財務・戦略的SWOT分析
    Informa PLC (INF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Electronic Arts Inc. (EA):企業の財務・戦略的SWOT分析
    Electronic Arts Inc. (EA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Sui Northern Gas Pipelines Ltd (SNGP):企業の財務・戦略的SWOT分析
    Sui Northern Gas Pipelines Ltd (SNGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • 21st Century Oncology Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary 21st Century Oncology Inc. (21st Century Oncology), a subsidiary of 21st Century Oncology Holdings, Inc., is a provider of integrated cancer care services (ICC). It operates through an integrated network of cancer treatment centers and affiliated physicians with specialization in radiation o …
  • Equinor ASA.:企業の戦略・SWOT・財務情報
    Equinor ASA. - Strategy, SWOT and Corporate Finance Report Summary Equinor ASA. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Electronics For Imaging, Inc. (EFII):企業の財務・戦略的SWOT分析
    Electronics For Imaging, Inc. (EFII) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Toa Corp (1885):企業の財務・戦略的SWOT分析
    Toa Corp (1885) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Evgen Pharma Plc (EVG):企業の財務・戦略的SWOT分析
    Summary Evgen Pharma Plc (Evgen Pharma), formerly Evgen Pharma Ltd is a clinical-stage drug development company. It is focused on the development of sulforaphane-based compounds for the treatment of cancer and neurological disease. Its pipeline product SFX-01 targets STAT3 signalling to inhibit stem …
  • Mecklenburg Electric Cooperative:企業の戦略的SWOT分析
    Mecklenburg Electric Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Peloton Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Peloton Therapeutics Inc (Peloton) is a clinical-stage pharmaceutical company that develops oral medicines and novel therapies for oncology. Its portfolio of pipeline products includes PT2977, PT2567 and PT2385. The company develops its products for the treatment of pulmonary arterial hypert …
  • ADInstruments Pty Ltd:企業の戦略的SWOT分析
    ADInstruments Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆